Cipla, India's third-largest drugmaker by sales, recently reported a net profit of around $63.6 million, a 45.2% increase in consolidated net profit from the same period last year.
The Indian multinational pharmaceutical manufacturer, through its company website, also said it gained a revenue of $1 million from operations for the quarter ending March 2023, a 9% year-on-year growth.
“I am pleased to share that we continue to make significant progress across our focused markets. We are excited for the upcoming year, wherein we look forward to deepening our leadership in branded markets and expanding our differentiated pipeline in the U.S.," said Cipla Managing Director and Global CEO Umang Vohra.
Vohra also said Cipla’s growth was driven by the company’s strong performance in its key domestic and North American markets, adding that compared to last year, revenue from its pharmaceutical business in India rose 3.5%, while revenue from North America surged 39%.
"Cipla is driven by this beautiful creed of caring for life. We are all about making sure that people have healthier lives,” Vohra added.
Currently, Cipla has 1,500+ products across various therapeutic categories across 80+ countries.